Optimization of the Evaluation of the Adrenal Function After Discontinuation of a Prolonged Therapy With Corticosteroids

August 28, 2014 updated by: Assistance Publique Hopitaux De Marseille

The study (forward-looking and opened) will concern 70 subjects having had a systemic prolonged treatment with corticosteroids for intestinal chronic inflammatory disease, recruited in the services of gastroenterology and endocrinology of the North Hospital of Marseille (France). The primary objective of the study is to estimate a new test, the "long" synacthen stimulation test, using an IM injection of 1 mg of delate synacthen, with regard to the definitive standard. Indeed, this long test could be realized in ambulatory conditions, and turn out more contributory than the definitive standard to estimate the capacities of answer of the adrenal glands in front of a prolonged stress, as it is the case during a surgical procedure for example.

The secondary objectives are: 1) to determine the relation between the value of basal cortisol and the peak of stimulation of cortisol during short and long tests. This could allow to clarify better the conditions in which it is absolutely necessary to realize a dynamic test, 2) to determine the relation between cortisol assay in the plasma and in the saliva. The sample of saliva is simple and non-invasive, and presents the advantage to be able to be realized in ambulatory conditions and by the patient himself.

The cortisonic withdrawal syndrome is another complication which can arise when a prolonged corticosteroid therapy is discontinued. Clinically, it looks like a chronic adrenocortical insufficiency, but with normal ranges of plasma cortisol. It is probably in touch with a physical dependence to the taking of above physiological doses of GC over a long period. Its physiopathology remains badly known, but could bring in a deficit of secretion of DHEA-S (dehydro-epiandrosterone sulphate), another hormone secreted by the adrenal glands. One of the secondary objectives of the study will consist in informing the variations of DHEA-S after a prolonged corticotherapy, in the basal state and after stimulation by the long synacthen stimulation test.

Study Overview

Status

Terminated

Detailed Description

Synthetic glucocorticoids (GC) are used in the treatment of numerous inflammatory or auto-immune diseases, in particular the intestinal chronic inflammatory diseases (Crohn's disease, chronic ulcerative colitis). In case of discontinuation of a prolonged (superior to 3-4 weeks) and systemic treatment, deleterious side effects are frequent, with in particular a risk of adrenocortical insufficiency and withdrawal cortisonic syndrome. Our protocol of medical research concerns these two complications, and aims at optimizing the evaluation of the adrenal function.

The adrenocortical insufficiency after prolonged corticotherapy is the most frequent cause of secondary adrenocortical insufficiency. It is due to the braking of the hypothalamo-pituitary-adrenal (HPA) axis which controls the endogenous secretion of cortisol. It is mostly transient, but can last several months, and exposes to a risk of acute decompensation. An adapted coverage with replacement doses of hydrocortisone (natural GC) is thus necessary during the treatment discontinuation, together with regular hormonal revaluations to track down the recovery of the adrenal function. These evaluations are based on biological measurements, because of the absence of specific clinical symptoms. At first, basal plasma cortisol at 08:00 am (physiological peak of the hormone) is assayed. A value lower than 8 µg / dl (220 nmol / l) allows to do the positive diagnosis of adrenal insufficiency and a value superior to 20 µg / dl (550 nmol / l) to exclude it. Between these 2 values, a doubt remains on the capacities of the adrenal glands to secrete enough cortisol in case of stress, and the realization of a dynamic test of stimulation is then necessary. The standard test used in common practice is the "short" synacthene stimulation test (fragment 1-24 of the ACTH, the hormone secreted by the pituitary gland and stimulating the secretion of cortisol) using an IV injection of 250 µg of immediate synacthen. The study (forward-looking and opened) will concern 70 subjects having had a systemic prolonged treatment with corticosteroids for intestinal chronic inflammatory disease, recruited in the services of gastroenterology and endocrinology of the North Hospital of Marseille (France). The primary objective of the study is to estimate a new test, the "long" synacthen stimulation test, using an IM injection of 1 mg of delate synacthen, with regard to the definitive standard. Indeed, this long test could be realized in ambulatory conditions, and turn out more contributory than the definitive standard to estimate the capacities of answer of the adrenal glands in front of a prolonged stress, as it is the case during a surgical procedure for example.

The secondary objectives are: 1) to determine the relation between the value of basal cortisol and the peak of stimulation of cortisol during short and long tests. This could allow to clarify better the conditions in which it is absolutely necessary to realize a dynamic test, 2) to determine the relation between cortisol assay in the plasma (classically used) and in the saliva ( which is validated for the evaluation of the other adrenal pathology as the Cushing's syndrome, but not still in the adrenocortical insufficiency after prolonged corticotherapy). The sample of saliva is simple and non-invasive, and presents the advantage to be able to be realized in ambulatory conditions and by the patient himself.

The cortisonic withdrawal syndrome is another complication which can arise when a prolonged corticosteroid therapy is discontinued. Clinically, it looks like a chronic adrenocortical insufficiency, but with normal ranges of plasma cortisol. It is probably in touch with a physical dependence to the taking of above physiological doses of GC over a long period. Its physiopathology remains badly known, but could bring in a deficit of secretion of DHEA-S (dehydro-epiandrosterone sulphate), another hormone secreted by the adrenal glands. One of the secondary objectives of the study will consist in informing the variations of DHEA-S after a prolonged corticotherapy, in the basal state and after stimulation by the long synacthen stimulation test.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Marseille, France
        • Assistance Publique-Hôpitaux de Marseille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Intestinal chronic inflammatory diseases (Crohn's disease, chronic ulcerative colitis)
  • Systemic prolonged treatment with corticosteroids during 2 months at least
  • Discontinuation of the treatment with corticosteroids for 6 weeks
  • Basal plasma cortisol between 8 and 20 µg / dl (220 to 550 nmol / l).

Exclusion Criteria:

  • Systemic prolonged treatment with corticosteroids because of an other disease than a intestinal chronic inflammatory disease
  • Pregnancy, breast feeding
  • Hypersensibility to synacthene
  • Basal plasma cortisol lower than 8 µg / dl (220 nmol / l) or superior to 20 µg / dl (550 nmol / l)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
To estimate a new test, the "long" synacthen stimulation test, using an IM injection of 1 mg of delate synacthen, with regard to the definitive standard.
Time Frame: 2 years
2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
To determine the relation between the value of basal cortisol and the peak of stimulation of cortisol during short and long tests - to determine the relation between cortisol assay in the plasma and in the saliva
Time Frame: 2 years
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sandrine BOULLU, Assistance Publique-Hôpitaux de Marseille

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2010

Primary Completion (Actual)

July 1, 2012

Study Completion (Actual)

July 1, 2012

Study Registration Dates

First Submitted

January 18, 2010

First Submitted That Met QC Criteria

January 18, 2010

First Posted (Estimate)

January 21, 2010

Study Record Updates

Last Update Posted (Estimate)

August 29, 2014

Last Update Submitted That Met QC Criteria

August 28, 2014

Last Verified

August 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • 2009/23
  • 2009-015730-30

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adrenocortical Insufficiency

Clinical Trials on "long" synacthen stimulation test

Subscribe